HALO · Halozyme Therapeutics
50 filings
HALO 10-Q Quarterly Reports
Halozyme Therapeutics - 50 quarterly reports
HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.
- 8-K · Jan 4, 2016
- 8-K · Jan 11, 2016
- 8-K · Jan 13, 2016
- 8-K · Jan 26, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 8-K · Mar 7, 2016
- 8-K · May 6, 2016
- 10-Q · May 9, 2016
- 8-K · May 9, 2016
- 8-K · Jun 8, 2016
- 8-K · Aug 9, 2016
- 10-Q · Aug 9, 2016
- 8-K · Sep 1, 2016
- 10-Q · Nov 7, 2016
- 8-K · Nov 7, 2016
- 8-K · Dec 19, 2016
- 8-K · Jan 5, 2017
- 8-K · Jan 9, 2017
- 8-K · Jan 10, 2017
- 8-K · Feb 28, 2017
- 10-K · Feb 28, 2017
- 8-K · May 5, 2017
- 10-Q · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 9, 2017
- 8-K · May 19, 2017
- 8-K · Jul 5, 2017
- 8-K · Aug 8, 2017
- 10-Q · Aug 8, 2017
- 8-K · Sep 29, 2017
- 10-Q · Nov 7, 2017
- 8-K · Nov 7, 2017
- 8-K · Jan 10, 2018
- 8-K · Jan 12, 2018
- 10-K · Feb 20, 2018
- 8-K · Feb 20, 2018
- 8-K · Mar 22, 2018
- 8-K · Apr 6, 2018
- 8-K · May 2, 2018
- 8-K · May 10, 2018
- 10-Q · May 10, 2018
- 10-Q · Aug 7, 2018
- 8-K · Aug 7, 2018
- 8-K · Sep 5, 2018
- 8-K · Sep 10, 2018
- 8-K · Nov 6, 2018
- 10-Q · Nov 6, 2018
- 8-K · Nov 26, 2018
- 8-K · Dec 13, 2018
- 8-K · Jan 9, 2019
- 10-K · Feb 21, 2019
- 8-K · Feb 21, 2019
- 8-K · May 3, 2019
- 10-Q · May 7, 2019
- 8-K · May 7, 2019
- 8-K · Jun 12, 2019
- 8-K · Aug 6, 2019
- 10-Q · Aug 6, 2019
- 8-K · Sep 4, 2019
- 8-K · Nov 5, 2019
- 8-K · Nov 12, 2019
- 10-Q · Nov 12, 2019
- 8-K/A · Nov 12, 2019
- 8-K · Nov 12, 2019
- 8-K · Nov 14, 2019
- 8-K · Nov 18, 2019
- 8-K · Jan 14, 2020
- 8-K · Jan 16, 2020
- 8-K · Feb 24, 2020
- 8-K · Feb 24, 2020
- 10-K · Feb 24, 2020
- 8-K · May 4, 2020
- 10-Q · May 11, 2020
- 8-K · May 11, 2020
- 8-K · Aug 10, 2020
- 10-Q · Aug 10, 2020
- 8-K · Nov 2, 2020
- 10-Q · Nov 2, 2020
- 8-K · Jan 11, 2021
- 8-K · Jan 13, 2021
- 10-K · Feb 23, 2021
- 8-K · Feb 23, 2021
- 8-K · Feb 23, 2021
- 8-K · Feb 25, 2021
- 8-K · Mar 1, 2021
- 8-K · May 3, 2021
- 8-K · May 5, 2021
- 8-K · May 7, 2021
- 8-K · May 10, 2021
- 10-Q · May 10, 2021
- 8-K · Aug 9, 2021
- 10-Q · Aug 9, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K/A · Nov 2, 2021
- 8-K · Dec 10, 2021
- 8-K · Dec 13, 2021
- 8-K · Dec 29, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 3, 2022
- 10-K · Feb 22, 2022
- 8-K · Feb 22, 2022
- 8-K · Mar 15, 2022
- 8-K · Mar 21, 2022
- 8-K · Apr 13, 2022
- 8-K · May 6, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 24, 2022
- 8-K/A · Aug 9, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Aug 15, 2022
- 8-K · Aug 16, 2022
- 8-K · Aug 18, 2022
- 8-K · Aug 19, 2022
- 8-K · Nov 8, 2022
- 10-Q · Nov 8, 2022
- 8-K · Jan 10, 2023
- 8-K · Feb 6, 2023
- 10-K · Feb 21, 2023
- 8-K · Feb 21, 2023
- 8-K · Feb 23, 2023
- 8-K · Mar 13, 2023
- 8-K · Mar 16, 2023
- 8-K · May 8, 2023
- 8-K · May 9, 2023
- 10-Q · May 9, 2023
- 10-Q · Aug 8, 2023
- 8-K · Aug 8, 2023
- 8-K · Sep 7, 2023
- 8-K · Nov 6, 2023
- 10-Q · Nov 6, 2023
- 8-K · Jan 17, 2024
- 10-K · Feb 20, 2024
- 8-K · Feb 20, 2024
- 8-K · Apr 26, 2024
- 10-Q · May 7, 2024
- 8-K · May 7, 2024
- 10-Q · Aug 6, 2024
- 8-K · Aug 6, 2024
- 10-Q · Oct 31, 2024
- 8-K · Oct 31, 2024
- 8-K · Jan 8, 2025
- 8-K · Feb 13, 2025
- 10-K · Feb 18, 2025
- 8-K · Feb 18, 2025
- 8-K · Mar 21, 2025
- 8-K · May 2, 2025
- 8-K · May 6, 2025
- 10-Q · May 6, 2025
- 10-Q · Aug 5, 2025
- 8-K · Aug 5, 2025
- 8-K · Oct 1, 2025
- 8-K · Oct 3, 2025
- 8-K · Oct 6, 2025
- 8-K · Oct 14, 2025
- 10-Q · Nov 3, 2025
- 8-K · Nov 3, 2025
- 8-K · Nov 5, 2025
- 8-K · Nov 7, 2025
- 8-K · Nov 12, 2025
- 8-K · Nov 24, 2025
- 8-K · Dec 8, 2025
- 8-K · Dec 9, 2025
- 8-K · Jan 28, 2026
- 8-K · Feb 17, 2026
- 10-K · Feb 17, 2026
- 8-K · Mar 12, 2026
- 8-K · Apr 24, 2026
- 8-K · Apr 30, 2026
- 8-K · May 7, 2026
- 8-K · May 11, 2026
- 10-Q · May 11, 2026
- 8-K · Jul 2, 2026
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026
- 8-K · Aug 18, 2026
- 8-K · Sep 16, 2026
- 8-K · Sep 18, 2026
- 8-K · Sep 22, 2026
- 8-K · Sep 30, 2026
- 10-Q · Nov 5, 2026
- 8-K · Nov 5, 2026
- 2026-Q3Nov 5, 2026
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2026
Halozyme Therapeutics (HALO) reported a strong third quarter for 2026, demonstrating significant growth in revenues and robust operational performance. Total revenues surged by 44% year-over-year to $493.0 million, primarily driven by a substantial 44% increase in royalty income, reaching $341.0 million. This growth was fueled by strong sales of key partner products utilizing Halozyme's ENHANZE technology, notably VYVGART Hytrulo and DARZALEX SC. Product sales also saw a significant uplift of 46% to $137.3 million, largely attributed to increased demand for bulk rHuPH20 and continued market growth for proprietary product XYOSTED. Operating expenses increased by 45% to $198.0 million, impacted by higher cost of sales, increased amortization of intangibles due to recent acquisitions (Elektrofi and Surf Bio), and elevated research and development and SG&A expenses. Despite the rise in operating expenses, the company maintained strong profitability, with net income growing to $247.0 million, a 41% increase compared to the prior year's quarter, and diluted earnings per share rising to $2.01. The company also strengthened its financial position by issuing $1.5 billion in convertible notes in September 2026, enhancing its liquidity which stood at $1.07 billion in cash, cash equivalents, and marketable securities as of September 30, 2026. Halozyme continues to actively manage its capital structure, including ongoing share repurchase programs.
- 2026-Q2Aug 6, 2026
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2026
Halozyme Therapeutics, Inc. reported a strong second quarter of 2026, with total revenues of $481.0 million versus $325.7 million in the prior-year quarter, and net income of $229.9 million, or $1.90 per diluted share, compared with $165.2 million, or $1.33 per diluted share, a year earlier. Royalties of $307.7 million rose from $205.6 million, driven by sales uptake of ENHANZE partner products such as VYVGART Hytrulo and DARZALEX SC. Product sales, net increased to $129.6 million, led by bulk rHuPH20 sales of $59.6 million, and revenues under collaborative agreements were $43.7 million, including $35.5 million of upfront license and target nomination fees. Operating income rose to $287.7 million from $202.4 million, although amortization of intangibles, research and development, and SG&A expenses all increased, partly reflecting the Elektrofi and Surf Bio acquisitions completed in late 2025. Capital allocation was a major focus during the quarter. The company repurchased 4.8 million shares for $332.7 million in the second quarter, completed its February 2024 $750.0 million repurchase program in June 2026, and authorized a new program of up to $1.0 billion through December 31, 2028. Cash and cash equivalents were $163.1 million and marketable securities were $67.9 million at June 30, 2026, totaling $231.0 million. Total long-term debt, net, plus the current portion stood at $2.15 billion, consisting mainly of convertible notes, and the revolving credit facility of $750 million was undrawn. Management stated that existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next 12 months. The filing also flags a risk tied to the Elektrofi acquisition: a partner is evaluating a potential return of a Hypercon target and will make a decision by February 2027. If the partner returns the target without nominating an alternative with similar future cash flows, the company would need to evaluate its acquired customer relationship intangibles and goodwill, which could lead to a material interim impairment charge. The company also disclosed that it is not party to any legal proceedings expected to have a material adverse effect, while noting litigation costs in connection with a patent infringement case within SG&A.
- 2026-Q1May 11, 2026
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2026
Halozyme Therapeutics, Inc. reported first-quarter 2026 total revenues of $376.7 million, up from $264.9 million a year earlier, driven primarily by royalties of $240.7 million (versus $168.2 million) and product sales, net of $130.4 million (versus $78.0 million). Net income rose to $150.0 million, or $1.22 per diluted share, compared with $118.1 million, or $0.93 per diluted share, in the prior-year quarter. Royalty growth was led by DARZALEX, VYVGART Hytrulo and Phesgo, and bulk rHuPH20 sales increased to $73.5 million from $27.0 million. Operating expenses rose to $192.2 million from $123.3 million, reflecting cost of sales, amortization tied to the Elektrofi acquisition, higher research and development and higher SG&A. At March 31, 2026, cash and cash equivalents were $309.7 million and cash, cash equivalents and marketable securities totaled $318.6 million. Total debt principal was $2.18 billion across the 2027, 2028, 2031 and 2032 convertible notes, and the $750 million revolving credit facility was undrawn. Net cash provided by operating activities was $180.1 million. The company stated that its current cash and marketable securities will be sufficient to fund operations for at least the next 12 months. Subsequent to quarter end, in May 2026, the Board authorized a new share repurchase program of up to $1 billion through December 31, 2028, with an expectation of buying back at least $400 million of shares in 2026. The filing also discloses new collaborations, including GSK, Oruka and Vertex, and notes that a partner is evaluating a potential target return by September 2026, which could trigger a material interim impairment charge to intangibles and/or goodwill.
- 2025-Q3Nov 3, 2025
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2025
Halozyme Therapeutics, Inc. reported third-quarter 2025 total revenues of $354.3 million, up from $290.1 million a year earlier, with net income of $175.2 million (diluted EPS $1.43, versus $1.05). Royalties were $236.0 million, up from $155.1 million, driven mainly by VYVGART Hytrulo, DARZALEX SC and Phesgo. For the nine months, total revenues were $944.8 million and net income was $458.5 million, with net cash provided by operating activities of $432.5 million. Cash, cash equivalents and marketable securities totaled $702.0 million at September 30, 2025, and management states these are sufficient to fund operations for at least the next 12 months. The company repurchased $342.4 million of common stock in the nine months under its $750.0 million program, with $92.3 million used in the third tranche as of quarter-end. The 2028 Convertible Notes ($720.0 million principal) were reclassified to current debt because their conditional conversion feature was triggered, and total current liabilities rose to $837.2 million. The filing states that the company agreed in September 2025 to acquire Elektrofi, Inc. for $750 million upfront plus up to three $50 million milestone payments, with closing expected in the fourth quarter of 2025 subject to antitrust review. The company also filed a patent infringement lawsuit against Merck in April 2025 concerning its MDASE technology, and notes that Otter discontinued marketing OTREXUP in August 2025.
- 2025-Q2Aug 5, 2025
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2025
Halozyme Therapeutics, Inc. reported a strong second quarter of 2025 in its Form 10-Q filed August 5, 2025. Total revenues were $325.7 million for the three months ended June 30, 2025, up from $231.4 million a year earlier, and $590.6 million for the six months, up from $427.2 million. Royalties were the main driver at $205.6 million for the quarter (up 65%), reflecting continued uptake of DARZALEX SC, VYVGART Hytrulo and Phesgo. Net income was $165.2 million for the quarter, or $1.33 per diluted share, compared with $93.2 million and $0.72 per diluted share a year earlier. Operating income for the quarter was $202.4 million. The balance sheet shows cash, cash equivalents and marketable securities of $548.2 million as of June 30, 2025, against long-term debt, net, of $1.51 billion, which consists of the 2027 and 2028 convertible notes. Stockholders' equity fell to $332.7 million from $363.8 million at December 31, 2024, largely due to share repurchases. The company repurchased 5.8 million shares in the second quarter for $303.5 million, and the six-month cash flow statement shows $303.5 million of repurchases of common stock. Net cash provided by operating activities was $253.9 million for the six months. The company stated that it believes its current cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next 12 months. The filing also disclosed a patent infringement lawsuit filed in April 2025 against Merck Sharp & Dohme Corp. concerning its MDASE subcutaneous delivery technology, and noted that Merck has challenged certain related U.S. patents in post-grant review proceedings at the PTAB.
- 2025-Q1May 6, 2025
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2025
Halozyme Therapeutics, Inc. reported first-quarter 2025 total revenues of $264.9 million, up from $195.9 million in the prior-year quarter, with royalties of $168.2 million (up 39%) as the largest driver. Product sales, net rose to $78.0 million, led by bulk rHuPH20 sales of $27.0 million, and revenues under collaborative agreements were $18.6 million, including a $15.0 million sales-based milestone. Operating income was $141.5 million versus $95.5 million a year earlier, and net income was $118.1 million, or $0.93 per diluted share, compared with $76.8 million, or $0.60 per diluted share. The balance sheet shows cash, cash equivalents and marketable securities of $747.9 million as of March 31, 2025, against long-term debt, net of $1.51 billion, which consists of the 2027 and 2028 convertible notes with total principal of $1.525 billion. Net cash from operating activities was $154.2 million. During the quarter the company completed a $250.0 million accelerated share repurchase, retiring 4.7 million shares at $53.95 per share, and it stated that $500.0 million remained available under the February 2024 program. Management stated that current cash and marketable securities are sufficient to fund operations for at least the next 12 months. The filing also notes subsequent developments, including the April 2025 filing of a patent infringement lawsuit against Merck Sharp & Dohme Corp. over its MDASE technology, and several partner regulatory approvals in Europe and the U.S., such as Janssen's SC RYBREVANT approval in the EU and argenx's FDA approval of a VYVGART Hytrulo prefilled syringe. The company also disclosed that its CEO, Helen Torley, adopted Rule 10b5-1 trading arrangements covering up to 628,492 shares in total.
- 2024-Q3Oct 31, 2024
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2024
Halozyme Therapeutics, Inc. reported third-quarter 2024 results in this Form 10-Q filed October 31, 2024. Total revenues for the three months ended September 30, 2024 were $290.1 million, up from $216.0 million a year earlier, and net income was $137.0 million, or $1.05 per diluted share, compared with $81.8 million, or $0.61 per diluted share, in the prior-year quarter. Royalties rose to $155.1 million from $114.4 million, driven by sales uptake of DARZALEX SC by Janssen and Phesgo by Roche, and revenues under collaborative agreements increased to $48.4 million, including a $27.0 million upfront license and target nomination fee. For the nine months ended September 30, 2024, total revenues were $717.3 million and net income was $307.1 million. At September 30, 2024, cash, cash equivalents and marketable securities totaled $666.3 million, and the company stated this is sufficient to fund operations for at least the next twelve months. Total assets were $2.12 billion and total stockholders' equity was $452.7 million, compared with $83.8 million at December 31, 2023. Long-term debt, net was $1.50 billion, consisting of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028, both with principal of $1.525 billion in total. Net cash provided by operating activities for the nine months was $300.6 million. The company completed a $750.0 million capital return program in June 2024 and authorized a new $750.0 million repurchase program in February 2024; no shares were repurchased in the third quarter of 2024. The filing also highlights recent partner milestones, including the September 2024 expansion of argenx's collaboration to six targets with $30.0 million in upfront payments, FDA approval of OCREVUS ZUNOVO with ENHANZE, and FDA approval of TECENTRIQ HYBREZA with ENHANZE, which resulted in a $12.0 million milestone payment. The company states that it is not a party to any legal proceedings expected to have a material adverse effect.
- 2024-Q2Aug 6, 2024
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2024
Halozyme Therapeutics, Inc. reported second-quarter 2024 total revenues of $231.4 million, up from $221.0 million in the prior-year quarter, and net income of $93.2 million, or $0.72 per diluted share, versus $74.8 million, or $0.56 per diluted share, a year earlier. Royalties rose to $124.9 million from $111.7 million, driven by continued uptake of Phesgo by Roche and the recent launches of VYVGART Hytrulo by argenx and Teriparatide by Teva in the U.S. Proprietary product sales grew to $44.1 million from $32.3 million, while bulk rHuPH20 sales and device partnered product sales declined on timing of partner demand. Revenues under collaborative agreements fell to $27.5 million from $35.4 million, which management attributed to the timing of milestones achieved. For the first six months of 2024, total revenues were $427.2 million and net income was $170.1 million, or $1.32 per diluted share. Cash, cash equivalents and marketable securities totaled $529.0 million at June 30, 2024, and the company stated these balances are sufficient to fund operations for at least the next twelve months. Net cash provided by operating activities was $185.2 million for the six months. The company completed its December 2021 $750.0 million share repurchase program in June 2024 and authorized a new $750.0 million program in February 2024. Long-term debt, net, was $1.50 billion, consisting of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028. Management noted that the company expects royalty revenue to grow as partner product sales of DARZALEX SC and Phesgo increase and as recently launched partner products, including VYVGART Hytrulo, Tecentriq SC and Ocrevus SC, ramp. The filing also states that a newly issued European patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until March 2029, and that the company is not party to any legal proceedings expected to have a material adverse effect.
- 2024-Q1May 7, 2024
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2024
Halozyme Therapeutics, Inc. reported first-quarter 2024 total revenues of $195.9 million, up from $162.1 million in the prior-year quarter, and net income of $76.8 million, or $0.60 per diluted share, compared with $39.6 million, or $0.29 per diluted share, a year earlier. Royalties rose to $120.6 million from $99.6 million, driven primarily by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche and the launch of Vyvgart by argenx. Revenues under collaborative agreements increased to $16.7 million, including $14.0 million in event-based development and regulatory milestones. Product sales, net declined to $58.6 million from $60.8 million, mainly due to lower bulk rHuPH20 sales from the timing of shipments to partners, partially offset by growth in proprietary product sales of $35.3 million. The balance sheet strengthened, with cash, cash equivalents and marketable securities totaling $463.5 million at March 31, 2024, and stockholders' equity rising to $177.8 million from $83.8 million at December 31, 2023. Operating cash flow was $129.4 million, compared with $86.96 million a year earlier. Long-term debt, net was $1.50 billion, consisting of the 2027 and 2028 Convertible Notes, and the $575 million revolving credit facility was undrawn. The company repurchased no shares in the quarter, and in February 2024 its board authorized a new $750.0 million capital return program. Management stated that the company believes its cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months. The filing notes expected fluctuations in collaborative and bulk rHuPH20 revenues tied to partner milestones and shipment timing, and recent partner regulatory milestones, including a $15.0 million milestone tied to the FDA's acceptance of BMS's Opdivo SC BLA.
- 2023-Q3Nov 6, 2023
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2023
Halozyme Therapeutics, Inc. reported third-quarter 2023 results in its Form 10-Q filed November 6, 2023. Total revenues for the three months ended September 30, 2023 were $216.0 million, up from $209.0 million a year earlier, and net income was $81.8 million, or $0.61 per diluted share, versus $61.6 million, or $0.44 per diluted share, in the prior-year quarter. Royalties rose to $114.4 million from $99.6 million, driven by DARZALEX SC sales by Janssen and Phesgo sales by Roche, while product sales, net increased to $86.6 million from $61.4 million, primarily due to bulk rHuPH20 sales and continued XYOSTED growth. Revenues under collaborative agreements fell to $15.0 million from $48.0 million, reflecting the timing of milestones. For the nine months ended September 30, 2023, total revenues were $599.2 million and net income was $196.2 million, or $1.45 per diluted share. Cash, cash equivalents and marketable securities totaled $483.3 million as of September 30, 2023, and management believes these balances will fund operations for at least the next twelve months. Total long-term debt, net, was $1.50 billion, consisting primarily of the 0.25% Convertible Notes due 2027 and the 1.00% Convertible Notes due 2028. The company repurchased 4,165,258 shares for $150.1 million in the first quarter of 2023 and had $250.0 million remaining under its $750 million repurchase program. The company also disclosed that it provided Lipocine notice of termination of the TLANDO license agreement effective January 31, 2024, which led to a $2.5 million impairment of the TLANDO product rights intangible asset and a $13.2 million gain from the remeasurement of the related contingent liability. Roche informed the company of a delay in the U.S. launch timing of Tecentriq SC, now expected in 2024.
- 2023-Q2Aug 8, 2023
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2023
Halozyme Therapeutics, Inc. reported strong second-quarter 2023 results, with total revenues of $221.0 million for the three months ended June 30, 2023, up from $152.4 million a year earlier, and net income of $74.8 million, compared with $22.7 million in the prior-year quarter. Royalties rose to $111.7 million, driven by continued uptake of DARZALEX SC by Janssen and Phesgo by Roche, plus new device royalty revenue from the Antares acquisition. Product sales, net increased to $73.9 million, and revenues under collaborative agreements reached $35.4 million, primarily from $33.0 million in milestone-related revenue tied to argenx's VYVGART Hytrulo approval and launch. For the six months ended June 30, 2023, total revenues were $383.2 million and net income was $114.4 million. The balance sheet shows cash, cash equivalents and marketable securities of $348.3 million at June 30, 2023, and total long-term debt, net, of $1.50 billion, consisting mainly of the 2027 and 2028 Convertible Notes. The 2024 Convertible Notes were converted in the first quarter of 2023, when the company paid approximately $13.5 million in cash. During the first quarter of 2023 the company repurchased 4.2 million shares for $150.0 million, and $250.0 million remains under its $750.0 million three-year repurchase program. The company states that its cash and marketable securities are sufficient to fund operations for at least the next twelve months. The filing highlights continued dependence on the ENHANZE collaboration network, with partner milestones and product launches cited as key drivers of future royalty growth. Management also notes that collaboration revenue fluctuates with partner milestone timing, and that the company's indebtedness and conditional conversion features on its convertible notes represent ongoing financial risks.
- 2023-Q1May 9, 2023
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2023
Halozyme Therapeutics, Inc.'s first quarter 2023 Form 10-Q reports total revenues of $162.1 million, up from $117.3 million in the prior-year quarter. Royalties rose to $99.6 million from $69.6 million, mainly driven by continued sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche, plus device royalties from the Antares acquisition. Product sales, net increased to $60.8 million from $22.1 million, reflecting proprietary products and device partnered products acquired with Antares. Revenues under collaborative agreements fell to $1.7 million from $25.5 million, as the prior-year period included a $25.0 million Chugai upfront license fee. Net income was $39.6 million, or $0.29 per diluted share, compared with $60.1 million, or $0.43 per diluted share, a year earlier. Operating expenses rose to $108.3 million from $41.6 million, with the increase including $17.8 million of amortization of intangibles, $37.4 million of SG&A and $18.0 million of R&D. Interest expense increased to $4.5 million from $1.8 million. Capital allocation was a major theme. The company repurchased 4.2 million shares for $150.1 million during the quarter, and cash and cash equivalents fell to $96.4 million from $234.2 million at year-end 2022. Cash, cash equivalents and marketable securities totaled $275.6 million at March 31, 2023, and management believes this is sufficient for at least the next twelve months. Total stockholders' equity declined to $65.9 million from $169.8 million, while long-term debt, net, was $1.49 billion, including the 2027 and 2028 Convertible Notes. The 2024 Convertible Notes were converted in full in March 2023 for $13.5 million in cash and 288,886 shares.
- 2022-Q3Nov 8, 2022
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2022
Halozyme Therapeutics, Inc. reported third-quarter 2022 total revenues of $209.0 million, up from $115.8 million in the prior-year quarter, with royalties of $99.6 million and product sales, net of $61.4 million. Net income was $61.6 million, or $0.44 per diluted share, compared with $216.6 million in the prior-year quarter, which benefited from a $142.5 million income tax benefia from the release of a valuation allowance. For the nine months ended September 30, 2022, total revenues were $478.6 million and net income was $144.4 million. Operating results for the quarter reflect the May 2022 acquisition of Antares Pharma, Inc., which added proprietary products (XYOSTED, TLANDO, NOCDURNA), device partnered products, and $27.2 million of quarterly intangible amortization. The company's total purchase consideration for Antares was $1,045.7 million. The balance sheet expanded substantially. Total assets were $1.86 billion at September 30, 2022, including goodwill of $199.5 million and intangible assets, net, of $948.9 million. Long-term debt, net, was $1.49 billion, reflecting the $720.0 million 1.00% Convertible Notes due 2028 issued in August 2022, the $805.0 million 0.25% Convertible Notes due 2027, and the remaining 2024 Convertible Notes. Cash, cash equivalents and marketable securities totaled $265.6 million. The company repurchased $200.0 million of common stock in 2022 and increased its revolving credit facility to $575 million in August 2022, with the revolver undrawn as of September 30, 2022. Management believes current cash and marketable securities will fund operations for at least the next twelve months. The filing also discloses that the company is terminating the NOCDURNA license agreement with Ferring effective October 2023, and that a contingent liability of $129.8 million assumed in the Antares deal relates to TLANDO. Cash flow from operations was $157.7 million for the nine months ended September 30, 2022, compared with $216.9 million in the prior-year period.
- 2022-Q2Aug 9, 2022
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2022
Halozyme Therapeutics, Inc. reported second-quarter 2022 results in this Form 10-Q, with total revenues of $152.4 million for the three months ended June 30, 2022, compared to $136.5 million a year earlier. Net income was $22.7 million, or $0.16 per diluted share, versus $91.5 million ($0.62 per diluted share) in the prior-year quarter. Royalty revenue rose to $85.3 million from $45.8 million, driven by DARZALEX FASPRO and Phesgo sales, while revenues under collaborative agreements fell to $20.7 million from $60.3 million. The results also reflect the May 24, 2022 acquisition of Antares Pharma, Inc., which was funded with cash on hand and a new $350 million revolving credit facility and $250 million term loan. Selling, general and administrative expenses rose to $57.5 million from $12.3 million, primarily due to one-time transaction and compensation costs tied to the acquisition. The acquisition materially changed the balance sheet. Goodwill of $199.5 million and intangible assets of $976.1 million were recorded, and total assets reached $1.78 billion at June 30, 2022, up from $1.10 billion at December 31, 2021. Total debt, net of discount, was $1.25 billion, including $120.0 million drawn on the revolver and $250.0 million on the term facility. The company also assumed a $130.0 million contingent liability tied to TLANDO, a product that received FDA approval on March 28, 2022 and launched in June 2022. Cash, cash equivalents and marketable securities totaled $209.4 million, which management said would be sufficient to fund operations for at least the next twelve months. The 10-Q also flags several risks for investors. The 2024 Convertible Notes were classified as a current liability because the conditional conversion feature was triggered as of June 30, 2022. The 2022 Credit Agreement carries a maximum consolidated net leverage ratio of 4.75 to 1.00, declining to 4.00 to 1.00, and a minimum interest coverage ratio of 3.00 to 1.00. Net cash from operating activities was $88.0 million for the six months, while investing outflows of $484.3 million were driven mainly by the acquisition. Company-level disclosures also note that the company repurchased no shares in the second quarter and that $600.0 million remained available under its second repurchase program.
- 2022-Q1May 10, 2022
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2022
Halozyme Therapeutics, Inc. reported first-quarter 2022 net income of $60.1 million, or $0.43 per diluted share, compared with $27.9 million, or $0.19 per diluted share, in the first quarter of 2021. Total revenues rose to $117.3 million from $89.0 million, driven mainly by royalties of $69.6 million (up from $36.9 million) on continued uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche. Revenues under collaborative agreements were $25.5 million, including a $25.0 million upfront payment from the new Chugai collaboration. Income tax expense rose to $14.3 million, reflecting a full quarter of tax expense after the valuation allowance release in 2021. Cash, cash equivalents and marketable securities totaled $786.1 million at March 31, 2022, which the company says will fund operations for at least the next twelve months. The most significant development is the April 12, 2022 merger agreement to acquire Antares Pharma, Inc. in a cash tender offer at $5.60 per share, for a total transaction value of approximately $960.0 million, expected to close in the first half of 2022. To finance it, Bank of America Securities and Bank of America, N.A. have committed to a $375 million senior secured term loan and a $75 million revolving credit facility. The company states that interest expense will increase once these credit facilities are in place. Balance-sheet items to note include total debt, net of discount, of $877.6 million at quarter-end, consisting of the 2024 and 2027 Convertible Notes, with the 2024 Convertible Notes classified as current because the conditional conversion feature was triggered. The company also stated that it expects its tax expense to approximate statutory rates beginning in 2022, which would significantly reduce net income relative to 2021 levels.
- 2021-Q3Nov 2, 2021
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2021
Halozyme Therapeutics, Inc. reported a strong third quarter and nine months of 2021, with total revenues of $115.8 million for the three months ended September 30, 2021 (up from $65.3 million) and $341.3 million for the nine months (up from $145.9 million). Royalties were $58.6 million in the quarter versus $23.9 million a year earlier, driven mainly by DARZALEX FASPRO sales by Janssen. Operating income for the quarter was $75.6 million, and net income was $216.6 million, or $1.48 per diluted share, which includes a $142.5 million income tax benefit from releasing the valuation allowance on federal and state deferred tax assets. The filing states that net income is therefore substantially and disproportionately higher than operating results, and that the company expects to begin recording income tax expense at approximately statutory rates from 2022. Balance sheet and capital activity changed meaningfully during the period. Cash, cash equivalents and marketable securities totaled $815.9 million at September 30, 2021. In March 2021 the company issued $805.0 million of 0.25% convertible notes due 2027 and used part of the proceeds for an induced conversion of $369.1 million of its 2024 convertible notes, which resulted in $21.0 million of induced conversion expense. The company repurchased 4.4 million shares for $189.7 million year to date and, in October 2021, completed its $550.0 million capital return program that began in November 2019. Management states the company believes current cash and marketable securities will fund operations for at least the next twelve months. The filing also highlights ongoing concentration and dependence risks. Revenue depends on collaboration partners such as Janssen, Roche, Baxalta, BMS and ViiV, and on the commercial success of their ENHANZE-based products. The filing notes the new risk factor added this quarter regarding the effective tax rate, as well as continuing COVID-19 uncertainty and reliance on third-party contract manufacturers.
- 2021-Q2Aug 9, 2021
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2021
Halozyme Therapeutics, Inc. reported strong second-quarter 2021 results, with total revenues of $136.5 million for the three months ended June 30, 2021, up from $55.2 million a year earlier, and operating income of $93.0 million. Royalties were $45.8 million versus $15.8 million, product sales, net were $30.4 million, and revenues under collaborative agreements were $60.3 million, driven by the ViiV upfront payment of $40 million and a $20 million Janssen sales-based milestone. Net income was $91.5 million, or $0.62 per diluted share, compared with $25.8 million, or $0.19 per diluted share, in the prior-year quarter. For the six months, net income was $119.4 million. Balance sheet and capital structure changed significantly in the period. In March 2021 the company sold $805.0 million of 0.25% Convertible Senior Notes due 2027 and used the proceeds, together with cash, to induce conversion of $369.1 million of its 1.25% Convertible Notes due 2024. Cash, cash equivalents and marketable securities totaled $755.3 million at June 30, 2021, and management stated these balances are sufficient to fund operations for at least the next twelve months. Total stockholders' equity was $119.7 million, with an accumulated deficit of $342.3 million. The company also repurchased $125.0 million of common stock during the first half of 2021 under its capital return program, with $74.9 million remaining authorized. Operationally, the filing highlights continued growth in royalties from Janssen's DARZALEX FASPRO and new ENHANZE collaborations, including a June 2021 agreement with ViiV Healthcare. Management notes that COVID-19 has not yet caused material delays to ENHANZE milestone revenue, though the pandemic remains a stated risk. The 2024 Convertible Notes are classified as a current liability at June 30, 2021 because the conditional conversion feature was triggered.
- 2021-Q1May 10, 2021
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2021
Halozyme Therapeutics, Inc. reported total revenues of $89.0 million for the three months ended March 31, 2021, compared to $25.4 million in the same period of 2020. The increase was driven by royalties of $36.9 million (up from $16.8 million), product sales, net of $21.8 million (up from $8.1 million), and revenues under collaborative agreements of $30.3 million, including $30.0 million in milestone and other fees from the BMS and Janssen collaborations. Net income was $27.9 million, or $0.19 per diluted share, versus a net loss of $6.1 million in the prior-year quarter. The results include $21.0 million of induced conversion expense tied to the March 2021 conversion of $369.1 million of 2024 Convertible Notes. The balance sheet changed significantly in the quarter. In March 2021 the company issued $805.0 million of 0.25% Convertible Senior Notes due 2027, with net proceeds of approximately $784.9 million. Cash, cash equivalents and marketable securities totaled $764.3 million at March 31, 2021. Total stockholders' equity was $67.6 million, down from $151.0 million at December 31, 2020, reflecting $76.2 million of share repurchases and the cumulative effect of adopting ASU 2020-06. Total debt carrying amount was $873.8 million. The company stated it believes current cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months. Management highlighted collaborator milestones during the quarter, including $25 million recognized from BMS for advanced plans to start a Phase 3 nivolumab study, and $5 million from Janssen for Japanese approval of subcutaneous DARZALEX. Royalty growth was attributed mainly to DARZALEX FASPRO sales by Janssen. The filing also notes that the company repurchased 1.8 million shares for $76.2 million in the quarter and has repurchased a cumulative 19.4 million shares for $426.2 million under its $550.0 million program.
- 2020-Q3Nov 2, 2020
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2020
Halozyme Therapeutics, Inc. reported third-quarter 2020 total revenues of $65.3 million, up from $46.2 million a year earlier, and net income of $36.2 million, compared with a net loss of $25.0 million in the prior-year quarter. Results were driven by $32.0 million of development milestones recognized from the Roche and argenx collaborations and royalty revenue of $23.9 million, up from $16.6 million, mainly due to DARZALEX FASPRO sales by Janssen. Product sales, net fell to $9.0 million from $29.2 million, reflecting a one-off large bulk rHuPH20 partner order in 2019. For the nine months ended September 30, 2020, net income was $55.9 million versus a net loss of $37.8 million, and operating cash flow was $4.5 million. The company is now focused solely on its ENHANZE technology and Hylenex after halting development of PEGPH20 following the failed HALO-301 Phase 3 study in November 2019. Research and development expense fell to $7.7 million in the quarter from $30.5 million, and SG&A decreased to $11.7 million from $18.0 million, following a restructuring that cut roughly 55 percent of the workforce. Cash, cash equivalents and marketable securities totaled $346.7 million at September 30, 2020, which management says is sufficient to fund operations for at least the next twelve months. Capital allocation remained active: the company repurchased 5.4 million shares for $112.4 million year to date under a $550.0 million, three-year program, and carried $393.6 million of net convertible notes due 2024 with $460.0 million in principal. Management noted that interest expense rose to $5.0 million in the quarter, mainly from the convertible notes, and that the company expects future royalty revenue growth from recent partner launches, while COVID-19 and biosimilar pressures remain risks.
- 2020-Q2Aug 10, 2020
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2020
Halozyme Therapeutics, Inc. reported a return to net income for the second quarter of 2020, with net income of $25.8 million, or $0.19 per diluted share, compared with a net loss of $14.6 million in the prior-year quarter. Total revenues for the quarter were $55.2 million, up from $39.1 million, driven mainly by $33.0 million in revenues under collaborative agreements, including $25.0 million of variable consideration tied to Janssen's milestones and a $7.3 million BMS license fee. Royalties declined to $15.8 million from $18.1 million, mainly due to lower Herceptin SC sales by Roche, and product sales, net rose slightly to $6.3 million. Research and development expenses fell to $9.0 million from $33.9 million as the company halted PEGPH20 development following the failed HALO-301 study and restructured its operations around ENHANZE, a restructuring that involved a staff reduction of approximately 55 percent of the total workforce. The balance sheet remains modest in size. As of June 30, 2020, cash, cash equivalents and marketable securities totaled $385.4 million, and the company stated it believes these resources are sufficient to fund operations for at least the next twelve months. Long-term debt, net, was $390.1 million, consisting primarily of the $460.0 million aggregate principal of 1.25% Convertible Senior Notes due 2024. During the six months ended June 30, 2020, the company repurchased $53.6 million of common stock, and it repaid its Royalty-backed Loan and its Oxford and SVB loan in full during the period or prior year. Stockholders' equity increased to $105.6 million from $91.8 million at year-end 2019. Management highlighted several partner milestones in the quarter, including FDA approval of Phesgo, EU approval and launch of subcutaneous DARZALEX, and US FDA approval of DARZALEX FASPRO with a $15 million milestone payment. The filing also notes uncertainty around the duration and economic impact of COVID-19 on partners, suppliers and operations, and that the company's revenue and royalties remain dependent on collaborator development and commercialization efforts.
- 2020-Q1May 11, 2020
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2020
Halozyme Therapeutics, Inc. reported a first-quarter 2020 net loss of $6.1 million, compared with net income of $1.8 million in the prior-year quarter. Total revenues were $25.4 million, down from $56.9 million, mainly because the prior-year quarter included $30.0 million in upfront license fees from the argenx collaboration. Royalties were $16.8 million, versus $18.0 million a year earlier, and product sales, net were $8.1 million. Research and development expense fell to $10.2 million from $31.3 million, reflecting the discontinuation of PEGPH20 development after the HALO-301 Phase 3 study failed its primary endpoint in November 2019. The company also reduced its workforce by approximately 55 percent. Capital allocation and liquidity dominated the quarter. Halozyme repurchased about 3.2 million shares for $51.6 million in March 2020, and cumulative repurchases under its $550.0 million program reached $251.6 million. Cash, cash equivalents and marketable securities totaled $368.2 million at March 31, 2020, and management stated these resources are sufficient for at least the next twelve months. Total stockholders' equity fell to $58.0 million from $91.8 million at December 31, 2019. Long-term debt is primarily the $460.0 million 1.25% Convertible Senior Notes due 2024, which were issued in November 2019 and carry a conversion price of approximately $23.85 per share. The filing notes that COVID-19 could disrupt partner development timelines, contract manufacturing and Hylenex sales, though management said it had not identified material delays to date. Recent milestones include the FDA approval of DARZALEX FASPRO in May 2020, a CHMP positive opinion for the daratumumab SC formulation in April 2020, and a Roche BLA for fixed-dose Perjeta and Herceptin with a PDUFA date of October 18, 2020. The company expects to achieve sustainable profitability beginning in the second quarter of 2020, and it projects that the Royalty-backed Loan will be repaid in that quarter.
- 2019-Q3Nov 12, 2019
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2019
Halozyme Therapeutics, Inc. reported a third-quarter 2019 net loss of $25.0 million, or $0.17 per share, on total revenues of $46.2 million, compared with a net loss of $27.9 million, or $0.19 per share, in the third quarter of 2018. For the nine months ended September 30, 2019, total revenues were $142.3 million, including $45.0 million recognized in connection with the argenx collaboration, and the net loss was $37.8 million, or $0.26 per share. Royalty revenue declined to $16.6 million for the quarter from $18.7 million, while product sales, net rose to $29.2 million from $6.3 million, driven mainly by bulk rHuPH20 sales to Janssen. Cash, cash equivalents and marketable securities totaled $238.0 million at September 30, 2019. The filing's most significant subsequent events are the November 4, 2019 announcement that the HALO-301 Phase 3 study of PEGPH20 in metastatic pancreatic cancer failed to reach its primary overall survival endpoint, and the resulting decision to halt PEGPH20 development, close oncology operations and focus solely on the ENHANZE technology. The company expects a workforce reduction of approximately 55%, or about 160 positions, with restructuring charges of approximately $17.0 million and lease and contract cancellation charges of $8.0 million to $10.0 million in the fourth quarter of 2019. Management anticipates becoming sustainably profitable beginning in the second quarter of 2020, and announced a capital return program to repurchase up to $350.0 million of common stock over three years. Management believes existing cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months. The company's Royalty-backed Loan, with an outstanding balance of $35.3 million, is estimated to be repaid in the second quarter of 2020, and the Oxford and SVB term loan had a balance of $28.5 million at quarter end.
- 2019-Q2Aug 6, 2019
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2019
Halozyme Therapeutics, Inc. reported a second quarter 2019 net loss of $14.6 million, or $(0.10) per share, compared to a net loss of $22.9 million, or $(0.16) per share, in the second quarter of 2018. Total revenues for the quarter were $39.1 million, up from $35.2 million a year earlier, driven primarily by $15.0 million recognized from the argenx collaboration and $10.0 million in upfront license and target nomination fees. Royalty revenue declined to $18.1 million from $20.0 million, mainly reflecting lower Herceptin SC sales by Roche. For the six months ended June 30, 2019, the net loss narrowed to $12.8 million from $50.4 million, and net cash used in operating activities was $29.2 million compared to $41.0 million a year earlier, mainly due to $40.0 million of cash received related to the argenx license fees. As of June 30, 2019, cash, cash equivalents and marketable securities totaled $287.5 million, and the company stated that these resources should be sufficient to fund operations for at least the next twelve months. Research and development expense for the PEGPH20 program fell to $28.7 million in the quarter from $35.4 million, reflecting completed enrollment in HALO-301, while selling, general and administrative expense rose to $17.3 million as the company prepares for a potential commercial launch of PEGPH20. The filing states that the final overall survival analysis for the Phase 3 HALO-301 trial is projected for mid-September 2019, with top-line results expected by December 2019. Debt remains a notable component of the balance sheet, with the Royalty-backed Loan outstanding at $52.0 million and the Oxford and SVB term loan at $32.9 million as of June 30, 2019. The company estimates the Royalty-backed Loan will be repaid in the second quarter of 2020. Accumulated deficit stood at $544.3 million.
- 2019-Q1May 7, 2019
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2019
Halozyme Therapeutics, Inc. reported a net income of $1.8 million for the three months ended March 31, 2019, compared with a net loss of $27.5 million in the prior-year period. Total revenues rose to $56.9 million from $30.9 million, driven mainly by a $30.0 million upfront license fee from the argenx collaboration, which was recognized as revenue under collaborative agreements. Royalty revenue declined to $18.0 million from $20.9 million, mainly reflecting lower Herceptin SC sales by Roche, and the company expects royalties to be flat or decline in the near term due to biosimilars in Europe. Research and development expenses fell to $31.3 million from $38.0 million, as PEGPH20 clinical trial activity decreased following completion of enrollment in the HALO-301 Phase 3 study. Selling, general and administrative expenses rose to $18.0 million from $13.6 million, mainly due to market research ahead of a potential PEGPH20 commercial launch. Operating cash use narrowed to $4.4 million from $22.2 million, and the company had cash, cash equivalents and marketable securities of $328.7 million at March 31, 2019. The company states that its existing cash, cash equivalents and marketable securities are sufficient to fund operations for at least the next twelve months, while noting it may need additional financing and that its accumulated deficit was $529.6 million. The filing also notes that the FDA changed the primary endpoint of the Phase 3 HALO-301 study to overall survival, with topline results expected in the second half of 2019.
- 2018-Q3Nov 6, 2018
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2018
Halozyme Therapeutics, Inc. reported a net loss of $27.9 million for the third quarter of 2018 on total revenues of $25.6 million, compared with net income of $2.7 million and total revenues of $63.7 million in the third quarter of 2017. For the nine months ended September 30, 2018, the net loss was $78.2 million on total revenues of $91.6 million. Royalty revenue grew to $18.7 million in the quarter (from $17.1 million) and $59.6 million year to date (from $45.8 million), driven by higher sales of MabThera SC and Herceptin SC by Roche and HYQVIA by Baxalta. Revenue from collaborative agreements fell sharply versus the prior year because the 2017 quarter included a $30.0 million upfront license fee from the Roche collaboration. Research and development spending rose to $35.5 million in the quarter and $113.6 million year to date, with PEGPH20 program expenses increasing on clinical trial activity. Cash, cash equivalents and marketable securities totaled $364.4 million at September 30, 2018, and management believes this is sufficient to fund operations for at least the next twelve months. Net cash used in operating activities was $60.0 million for the nine months. Long-term debt consists of a $150 million royalty-backed loan and a Loan and Security Agreement with Oxford Finance and SVB, with an outstanding term loan balance of $45.5 million. Subsequent to quarter end, the company entered into an agreement with Roche for one additional exclusive ENHANZE target and an option on two more, for an upfront payment of $25.0 million. The filing also notes that the Phase 3 HALO-301 trial of PEGPH20 in stage IV pancreatic cancer expects to achieve its target number of PFS events between December 2018 and February 2019.
- 2018-Q2Aug 7, 2018
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2018
Halozyme Therapeutics, Inc. reported a net loss of $22.9 million for the second quarter of 2018 (versus $30.8 million in the second quarter of 2017) on total revenues of $35.2 million, and a net loss of $50.4 million for the six months ended June 30, 2018 on total revenues of $66.1 million. Royalty revenue was the main growth driver, rising to $20.0 million in the quarter from $14.7 million a year earlier, driven by higher sales of Herceptin SC, MabThera SC (RITUXAN HYCELA in the U.S.) by Roche and HYQVIA by Baxalta. Product sales, net fell to $4.5 million from $12.8 million, mainly because bulk rHuPH20 sales to Roche and Baxalta declined, while collaborative agreement revenue rose to $10.7 million, including $10.0 million in event-based development milestones and other fees. Research and development expense rose to $40.1 million in the quarter, with PEGPH20 spending up to $35.4 million from $32.0 million on increased clinical trial activity. Cash, cash equivalents and marketable securities totaled $398.9 million at June 30, 2018, and management states this is sufficient to fund operations for at least the next twelve months. The company's long-term debt includes a $116.5 million Royalty-backed Loan (interest rate 10.25% as of June 30, 2018) and a term loan of $49.5 million under its Oxford and SVB loan agreement. Accumulated deficit stood at $501.5 million. The lead pipeline asset is PEGPH20, which is in a Phase 3 trial (HALO-301) in stage IV pancreatic cancer, with the company projecting the target number of PFS events to be reached between December 2018 and February 2019. The company also disclosed that a Phase 1b/2 study of PEGPH20 with Keytruda in gastric cancer did not meet its threshold to continue development in that indication, and that SWOG stopped enrollment in its Phase 1b/2 study in March 2017 after a futility analysis.
- 2018-Q1May 10, 2018
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2018
Halozyme Therapeutics, Inc. reported a net loss of $27.5 million for the three months ended March 31, 2018, compared with $32.9 million in the same period of 2017. Total revenues rose to $30.9 million from $29.6 million, driven by royalties of $20.9 million (up from $14.0 million), partially offset by lower product sales, net of $6.8 million (down from $11.4 million), mainly due to reduced sales of bulk rHuPH20 to Roche and Baxalta. Research and development expense was $38.0 million, with PEGPH20 program spending of $32.5 million, up from $27.7 million. Adoption of ASC 606 on January 1, 2018 was applied under the modified retrospective approach, and the filing states it increased revenues by $1.1 million in the quarter. At March 31, 2018, cash, cash equivalents and marketable securities totaled $433.7 million, and the company stated these are sufficient to fund operations for at least the next twelve months. Cash used in operating activities was $22.2 million for the quarter. Total debt carried on the balance sheet includes the $131.8 million Royalty-backed Loan, held by subsidiary Halozyme Royalty LLC and non-recourse to Halozyme, and a $53.4 million term loan under the Oxford and SVB Loan Agreement. Stockholders' equity rose to $265.1 million from $208.4 million at year-end 2017. The lead pipeline asset, PEGPH20, is in Phase 3 testing (HALO-301) in stage IV pancreatic ductal adenocarcinoma, with the filing projecting the target number of PFS events will be reached between December 2018 and February 2019. The filing also reports that SWOG's Phase 1b/2 all-comers study of PEGPH20 with modified FOLFIRINOX reported median overall survival of 7.7 months in the PEGPH20 arm versus 14.4 months in the control arm, and that the HALAVEN collaboration with Eisai will not proceed to Phase 2.
- 2017-Q3Nov 7, 2017
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2017
Halozyme Therapeutics, Inc. reported its third-quarter 2017 results in this Form 10-Q, filed November 7, 2017. Total revenues for the three months ended September 30, 2017 were $63.7 million, up from $31.9 million a year earlier, driven mainly by a $30.0 million upfront license fee from the 2017 Roche Collaboration. The company reported net income of $2.7 million for the quarter, compared with a net loss of $28.9 million in the prior-year period. For the nine months, the company still posted a net loss of $60.9 million on total revenues of $127.0 million. Cash, cash equivalents and marketable securities totaled $316.9 million at September 30, 2017, which the company believes will fund operations for at least the next twelve months. The company's lead program, PEGPH20, is in Phase 3 testing (Halo 109-301) with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma. R&D expense for PEGPH20 rose to $29.3 million in the quarter from $24.2 million. The filing also notes a September 2017 agreement with Bristol-Myers Squibb, with an upfront payment of $105.0 million that became effective in November 2017 and is expected to be recognized as $101.4 million of revenue in the fourth quarter of 2017. Management notes the company expects to adopt ASC Topic 606 on January 1, 2018 using the modified retrospective approach and anticipates a material impact on its financial statements. Financing and capital structure changed during the period. In May 2017 the company sold 11.5 million shares, generating $134.9 million in net proceeds. Total debt includes a $151.3 million Royalty-backed Loan at Halozyme Royalty LLC and a $55.6 million term loan under the Oxford and SVB Loan Agreement. Stockholders' equity improved to $72.4 million from a deficit of $32.5 million at year-end 2016, and accumulated deficit reached $646.3 million.
- 2017-Q2Aug 8, 2017
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2017
Halozyme Therapeutics, Inc. reported a net loss of $30.8 million for the second quarter of 2017 (versus $26.9 million in the prior-year quarter) and a net loss of $63.7 million for the six months ended June 30, 2017. Total revenues were $33.8 million for the quarter, up slightly from $33.3 million, with royalties rising to $14.7 million from $12.3 million, while product sales, net declined to $12.8 million from $13.7 million. Research and development expense increased to $38.3 million, driven by PEGPH20 clinical trial activity, which rose 31% in the quarter. Selling, general and administrative expense was $13.1 million. The balance sheet strengthened during the period. In May 2017 the company completed an underwritten public offering of 11.5 million shares at $12.50 per share, generating $134.9 million in net proceeds. Cash, cash equivalents and marketable securities totaled $297.5 million at June 30, 2017, and management believes this is sufficient to fund operations for at least the next twelve months. Stockholders' equity improved to $58.2 million from a deficit of $32.5 million at year-end 2016. Long-term obligations remain significant, including the $155.7 million Royalty-backed Loan and a $55.3 million term loan with Oxford and SVB. Clinically, the company's lead program is PEGPH20, which is in a Phase 3 study (Study 109-301) in stage IV pancreatic cancer. The filing notes that a Phase 1b/2 SWOG study (S1313) was stopped after its Data Monitoring Committee found PEGPH20 unlikely to show a statistically significant overall survival benefit in an all-comer population, with a higher rate of death in the PEGPH20 arm. Management states that other PEGPH20 studies continue unchanged.
- 2017-Q1May 9, 2017
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2017
Halozyme Therapeutics, Inc. reported a first-quarter 2017 net loss of $32.9 million, or $0.26 per share, versus a net loss of $19.8 million, or $0.16 per share, in the first quarter of 2016. Total revenues were $29.6 million, down from $42.5 million, driven mainly by lower revenues under collaborative agreements ($4.2 million versus $18.2 million, when $15.5 million of license and milestone revenue was recognized in 2016) and lower product sales, net ($11.4 million versus $12.9 million). Royalty revenue rose to $14.0 million from $11.4 million. Research and development expense declined to $36.9 million from $40.1 million, while selling, general and administrative expense rose to $12.6 million from $10.8 million. Net cash used in operating activities was $22.5 million. As of March 31, 2017, cash, cash equivalents and marketable securities totaled $179.0 million, and the company stated this is expected to fund operations for at least the next twelve months. Total stockholders' deficit was $58.5 million, and total debt includes the $158.9 million Royalty-backed Loan and $55.1 million Oxford and SVB term loan. The company said it may need additional capital and could raise funds through equity, debt, collaborations or asset monetization. The filing also details pipeline developments, including the SWOG study of PEGPH20 with modified FOLFIRINOX being stopped for futility after a higher rate of death was observed in the PEGPH20 arm, the ongoing Phase 3 Study 109-301 in stage IV pancreatic cancer, and a pending FDA action date of June 26, 2017 for rituximab SC.
- 2016-Q3Nov 7, 2016
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2016
Halozyme Therapeutics, Inc. reported its quarterly results for the period ended September 30, 2016 in this Form 10-Q. Total revenues for the three months were $31.9 million, up from $20.8 million a year earlier, and for the nine months were $107.7 million versus $82.8 million. Royalty revenue rose to $13.0 million for the quarter and $36.7 million for the nine months, primarily from increased sales of Herceptin SC by Roche. Net loss widened to $28.9 million for the quarter and $75.6 million for the nine months, driven mainly by research and development expenses of $109.5 million for the nine months, including higher PEGPH20 clinical trial spending. Cash, cash equivalents and marketable securities totaled $221.1 million at September 30, 2016, and the company stated these are expected to fund operations for at least the next twelve months. The balance sheet shows a shift in financing. In January 2016 the company received a $150 million Royalty-backed Loan through its subsidiary Halozyme Royalty LLC, which is non-recourse to Halozyme and secured by royalty payments from the Roche and Baxalta collaborations. In June 2016 it entered a new $70 million senior secured term loan with Oxford Finance and Silicon Valley Bank, drawing $55.0 million and using the proceeds to repay its prior loan. Long-term debt, net, rose to $199.8 million from $28.0 million, and total stockholders' deficit was $12.0 million at September 30, 2016, compared with equity of $43.0 million at December 31, 2015. Clinical development remained the central focus. The company said the Phase 3 study of PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Study 109-301) dosed its first patient in March 2016. Reporting of progression-free survival data from the Phase 2 Study 109-202 may move from the fourth quarter of 2016 into 2017. The company also discontinued the PRIMAL lung cancer study in August 2016, and Pfizer discontinued its bococizumab program in collaboration with Halozyme.
- 2016-Q2Aug 9, 2016
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2016
Halozyme Therapeutics, Inc. reported a net loss of $26.9 million for the three months ended June 30, 2016, compared with net income of $3.0 million in the prior-year quarter, and a net loss of $46.7 million for the six months. Total revenues were $33.3 million for the quarter versus $43.4 million a year earlier, driven by lower collaboration revenue after the $23.0 million AbbVie upfront fee recognized in Q2 2015. Royalty revenue rose to $12.3 million from $6.4 million, primarily on increased sales of Herceptin SC by Roche. Research and development expense nearly doubled to $35.5 million, mainly reflecting clinical trial activity for the lead oncology candidate PEGPH20. The balance sheet changed materially in 2016. Cash, cash equivalents and marketable securities totaled $230.0 million at June 30, 2016, and the company's stockholders' equity fell to $9.9 million from $43.0 million at December 31, 2015. Long-term debt, net, rose to $204.9 million, reflecting a $150 million Royalty-backed Loan received in January 2016 (outstanding balance $153.8 million) and a new $55.0 million senior secured term loan with Oxford Finance and Silicon Valley Bank entered in June 2016. Management states that current cash and marketable securities are sufficient to fund operations for at least the next twelve months, and projects a cash and cash equivalents balance of $170 million to $190 million at December 31, 2016. Clinical developments included the dosing of the first patient in the Phase 3 Study 109-301 of PEGPH20 in stage IV pancreatic cancer in March 2016, and final Stage 1 results from Study 109-202 presented at ASCO, where median progression-free survival in high-HA patients was 9.2 months in the PEGPH20 arm versus 6.0 months in the control arm. The company also disclosed that it discontinued the PRIMAL lung cancer study in August 2016.
- 2016-Q1May 9, 2016
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2016
Halozyme Therapeutics, Inc. reported a first quarter 2016 net loss of $19.8 million, or $0.16 per share, compared with a net loss of $15.1 million, or $0.12 per share, in the first quarter of 2015. Total revenues rose to $42.5 million from $18.7 million, driven by royalties of $11.4 million (up from $6.8 million, mainly from increased Herceptin SC sales by Roche), revenues under collaborative agreements of $18.2 million (up from $2.0 million), and product sales, net of $12.9 million (up from $9.9 million). Research and development expense increased to $40.1 million from $16.7 million, with PEGPH20 spending of $32.1 million versus $12.9 million, reflecting increased clinical trial activity, including the first patient dosed in the Phase 3 Study 109-301 in pancreatic cancer. At March 31, 2016, the company had cash, cash equivalents and marketable securities of approximately $238.6 million, versus $108.3 million at December 31, 2015 (cash of $43.3 million plus marketable securities of $65.0 million). In January 2016, its subsidiary Halozyme Royalty LLC received a $150 million Royalty-backed Loan secured by royalties from the Roche and Baxalta collaborations; the loan carries a rate of 8.75% plus three-month LIBOR and is non-recourse to Halozyme. Management believes current resources will fund operations for at least the next twelve months, and it anticipates cash and cash equivalents will increase by approximately $45 million to $65 million for 2016, including $25 million from Lilly and the $150 million loan. The company also states that it may need additional financing, and that its existing resources may not be adequate until it becomes profitable. Key program updates include the March 2016 dosing of the first patient in the Phase 3 PEGPH20 study in previously untreated stage IV pancreatic ductal adenocarcinoma, and an IDE approval for the Ventana companion diagnostic. The company expects to present mature progression-free survival and overall response rate data from Stage 2 of Study 109-202 in the fourth quarter of 2016.
- 2015-Q3Nov 9, 2015
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2015
Halozyme Therapeutics, Inc. reported a net loss of $24.5 million, or $0.19 per share, for the three months ended September 30, 2015, compared with a net loss of $20.3 million, or $0.16 per share, in the prior-year quarter. For the nine months ended September 30, 2015, the net loss was $36.5 million, or $0.29 per share, versus $63.1 million, or $0.52 per share, a year earlier. Total revenues for the nine months were $82.8 million, up from $45.0 million, driven largely by $23.0 million in license fees recognized from the AbbVie collaboration and royalty revenue of $21.4 million, primarily from increased sales of Herceptin SC by Roche. Research and development expense rose to $65.5 million for the nine months, with PEGPH20 spending of $52.6 million, reflecting increased clinical trial activity. At September 30, 2015, the company had cash, cash equivalents and marketable securities of approximately $123.7 million against bank debt of approximately $49.8 million. Management believes current resources are sufficient to fund operations for at least the next twelve months and anticipates total net cash burn of approximately $20 million to $30 million for 2015. The filing notes that existing resources may not be adequate until the company becomes cash flow positive, and that additional financing may be needed, which could cause dilution. The lead program, PEGPH20, is in Phase 2 testing in metastatic pancreatic cancer (Study 109-202), where a clinical hold in 2014 was lifted and enrollment resumed under a revised protocol. The company plans a Phase 3 study (Study 109-301) and states that an approved companion diagnostic is required before Phase 3 initiation. The filing also discloses a change-in-control severance framework adopted on November 4, 2015 for certain executives.
- 2015-Q2-AAug 11, 2015
Halozyme Therapeutics Quarterly Report (Amendment) for Q2 Ended Jun 30, 2015
Halozyme Therapeutics, Inc. filed this Amendment No. 1 on Form 10-Q/A to its Quarterly Report for the period ended June 30, 2015, originally filed with the SEC on August 10, 2015. The amendment was made solely to correct a typographical error in the number of common shares outstanding as of August 6, 2015, which is corrected from 12,771,772 to 127,771,772 shares. The company also filed new certifications by its principal executive officer and principal financial officer as exhibits, as required by Rule 12b-15. The amendment states that it contains only the sections and exhibits being amended and must be read together with the original Form 10-Q. It explicitly does not otherwise change or update the disclosures or financial information in the original filing, and it does not reflect events occurring after that original filing. For investors, this filing contains no new financial results, operating updates, or business developments. Its substantive content is the corrected share count and the refiled officer certifications. The financial disclosures themselves reside in the original Form 10-Q, which is not reproduced in this amendment.
- 2015-Q2Aug 10, 2015
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2015
Halozyme Therapeutics, Inc. reported a second quarter 2015 net income of $3.0 million on total revenues of $43.4 million, compared with a net loss of $16.3 million on revenues of $18.4 million in the same period of 2014. The quarter's results were driven primarily by a $23.0 million license fee recognized from the AbbVie collaboration, signed in June 2015, and by royalty revenue of $6.4 million, mainly from Roche's Herceptin SC. For the six months ended June 30, 2015, the company posted a net loss of $12.1 million on total revenues of $62.0 million, versus a net loss of $42.8 million in the prior-year period. Operating expenses rose in the quarter, with research and development at $21.2 million, up from $18.6 million, reflecting increased PEGPH20 clinical activity. At June 30, 2015, the company held cash, cash equivalents and marketable securities of approximately $140.7 million against bank debt of approximately $49.8 million, and total stockholders' equity was $50.2 million. Management states that current resources are sufficient to fund operations for at least the next twelve months and anticipates total net cash burn of approximately $20 million to $30 million for 2015. The filing states that the company's lead oncology program, PEGPH20, is in Phase 2 testing in metastatic pancreatic cancer, with a Phase 3 study (Study 109-301) planned following FDA feedback, and that thromboembolic event monitoring in the Phase 2 study could lead to another clinical halt if protocol changes do not reduce event rates. The filing also notes that the company has incurred aggregate net losses of approximately $462.5 million through June 30, 2015, and that its product revenues depend heavily on Hylenex recombinant, royalties from collaborator products, and collaboration payments that are largely outside the company's control. Management has decided to seek collaborations or explore strategic alternatives for non-oncology programs to concentrate resources on PEGPH20.
- 2015-Q1May 11, 2015
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2015
Halozyme Therapeutics, Inc. reported a net loss of $15.1 million, or $0.12 per share, for the three months ended March 31, 2015, compared with a net loss of $26.5 million, or $0.22 per share, in the prior-year quarter. Total revenues rose to $18.7 million from $12.0 million, driven primarily by royalties of $6.8 million (versus $0.8 million), which the filing attributes mainly to increased sales of Herceptin SC by Roche. Product sales, net were $9.9 million, and research and development expenses declined to $16.7 million from $21.4 million. As of March 31, 2015, cash, cash equivalents and marketable securities totaled approximately $128.5 million against bank debt of approximately $49.7 million. The company stated that these resources are sufficient to fund operations for at least the next twelve months, and it projects total net cash burn of approximately $35 million to $45 million for 2015. The company's strategic focus is its lead oncology program, PEGPH20. Following an FDA meeting in March 2015, Halozyme plans to proceed with a Phase 3 study (Study 109-301) in metastatic pancreatic cancer, with a design that could support marketing application based on either progression-free survival or overall survival. The FDA confirmed that an approved companion diagnostic is required before Phase 3 initiation. The company also disclosed that it intends to seek collaborations or explore strategic alternatives for its non-oncology programs, including diabetes. Research and development spending on PEGPH20 rose to $12.9 million from $6.7 million, and the company expects R&D expenses to increase in future periods. Risk factors highlighted in the filing include the thromboembolic event rate in Study 109-202, which was placed on clinical hold in April 2014 and may be halted again under pre-specified protocol rules, along with uncertainty around FDA requirements for a Hylenex recombinant label update for insulin pump use, and reliance on third-party contract manufacturers. Accumulated deficit reached $465.5 million as of March 31, 2015.
- 2014-Q3Nov 10, 2014
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2014
Halozyme Therapeutics, Inc. reported a net loss of $20.3 million for the third quarter of 2014 and $63.1 million for the nine months ended September 30, 2014, compared to $19.3 million and $61.5 million in the prior-year periods. Total revenues were $14.6 million for the quarter and $45.0 million for the nine months. Product sales, net, were $27.7 million for the nine months, up from $14.6 million, driven primarily by bulk rHuPH20 supply for Roche collaboration products and Hylenex recombinant sales. Royalty revenue began to appear, at $5.4 million for the nine months, mainly from Roche's Herceptin SC sales. Research and development expense fell to $60.0 million for the nine months from $75.7 million, reflecting lower Enhanze collaboration manufacturing costs, partly offset by higher PEGPH20 spending. At September 30, 2014, cash, cash equivalents and marketable securities totaled approximately $134.5 million against about $50 million of bank debt. The company completed an underwritten public offering in February 2014 that generated approximately $107.7 million in net proceeds. Management believes current resources will fund operations for at least the next twelve months and anticipates net cash burn of approximately $45 to $55 million for 2014, excluding offering proceeds. The company stated that it is focusing resources on PEGPH20, the lead oncology candidate, which received FDA Fast Track and Orphan Drug designations. It is seeking third-party collaborations or other strategic alternatives for its diabetes and dermatology programs, and it announced a workforce reduction of approximately 13% in November 2014. The filing also notes that the Study 202 PEGPH20 trial was placed on clinical hold in April 2014, resumed in July 2014 under a revised protocol, and remains subject to halt if thromboembolic event rates do not improve. Accumulated deficit reached $445.2 million.
- 2014-Q2Aug 11, 2014
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2014
Halozyme Therapeutics, Inc. reported its second quarter 2014 results in this Form 10-Q. Total revenues for the three months ended June 30, 2014 were $18.4 million, up from $14.5 million a year earlier, and net loss narrowed to $16.3 million from $22.9 million. Product sales, net rose to $9.5 million from $3.1 million, driven primarily by $6.0 million of bulk rHuPH20 product sales for Roche collaboration products. For the six months ended June 30, 2014, the net loss was $42.8 million, compared with $42.2 million a year earlier, and the accumulated deficit reached $424.9 million. The balance sheet strengthened materially during the period. Cash, cash equivalents and marketable securities totaled approximately $147.6 million at June 30, 2014, following net proceeds of approximately $107.7 million from a February 2014 public offering of 8.8 million shares at $13.00 per share. The company stated that its current cash, cash equivalents and marketable securities will be sufficient to fund operations for at least the next twelve months, and it anticipates net cash burn of approximately $45 to $55 million for 2014, excluding offering proceeds. Long-term debt, net was $49.8 million, under a term loan that matures January 1, 2018. Pipeline and collaboration developments included the June 2014 launch of Roche's MabThera SC in Europe, which triggered a $5.0 million sales-based payment, and the July 2014 resumption of enrollment in the Phase 2 PEGPH20 Study 202 after a clinical hold. The filing also reports that the ViroPharma and Intrexon collaborations were terminated effective May 2014, and that a July 31, 2014 FDA advisory committee voted 15-1 that HyQvia has a favorable benefit-risk profile, with Baxter expecting an FDA response in the third quarter of 2014.
- 2014-Q1May 12, 2014
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2014
Halozyme Therapeutics, Inc. reported a net loss of $26.5 million for the first quarter ended March 31, 2014, compared with $19.3 million in the prior-year quarter. Total revenues were $12.0 million, up slightly from $11.8 million, with product sales, net rising to $8.6 million from $1.5 million, driven mainly by $5.9 million of bulk rHuPH20 sales for Roche's Herceptin SC. Revenues under collaborative agreements fell to $2.6 million from $10.3 million, as reimbursements for research and development services and bulk supply declined. Operating expenses rose to $37.2 million, and research and development expense was $21.4 million, roughly flat year over year, while selling, general and administrative expense increased to $10.3 million from $7.6 million. The balance sheet strengthened materially. In February 2014 the company completed an underwritten public offering of 8,846,153 shares at $13.00 per share, generating about $107.7 million in net proceeds. Cash, cash equivalents and marketable securities totaled approximately $164.5 million at March 31, 2014, and management believes this is sufficient to fund operations for at least the next twelve months. The company also expects a total net cash burn of about $45 to $55 million for 2014, excluding offering proceeds. Long-term debt, net, stood at $49.8 million under a $50 million term loan with Oxford Finance and Silicon Valley Bank. The filing highlights regulatory and clinical developments that carry risk. On April 4, 2014, enrollment and dosing of PEGPH20 were temporarily halted in a Phase 2 pancreatic cancer study after a Data Monitoring Committee recommendation, and on April 8, 2014 the FDA placed a clinical hold on PEGPH20. Two collaborations were terminated in early 2014: ViroPharma (notified February 2014, effective 90 days after notice) and Intrexon (notified April 2014, effective 30 days after notice). The company also reported positive results in the CONSISTENT 1 trial for Hylenex recombinant in continuous subcutaneous insulin infusion, and a proof-of-concept HTI-501 cellulite trial met its primary endpoint.
- 2013-Q3Nov 8, 2013
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2013
Halozyme Therapeutics, Inc. reported a net loss of $19.3 million for the three months ended September 30, 2013 and $61.5 million for the nine months, compared with $20.0 million and $49.1 million in the prior-year periods. Total revenues rose to $16.0 million in the quarter from $5.3 million a year earlier, and to $42.3 million for the nine months from $20.5 million. Product sales, net increased to $10.0 million in the quarter, driven largely by $7.9 million of rHuPH20 API sales for Herceptin SC following its European approval, while revenues under collaborative agreements were $6.0 million. Research and development expense rose to $25.7 million in the quarter and $75.7 million for the nine months, led by clinical activity in the more physiologic insulin and PEGPH20 programs. The balance sheet shows a shift in liquidity. Cash and cash equivalents fell to $17.5 million from $99.5 million at December 31, 2012, although marketable securities of $47.8 million brought cash, cash equivalents and marketable securities to approximately $65.3 million. Total stockholders' deficit was $3.5 million at September 30, 2013, compared with equity of $48.9 million at year-end 2012. Net cash used in operating activities was $34.1 million for the nine months. Management believes current cash will fund operations for at least the next twelve months and anticipates total net cash burn of approximately $45 to $50 million for 2013. It does not expect revenues to fund operations until 2014 at the earliest. The filing also notes $360.1 million in accumulated deficit, a $30 million term loan from Oxford Finance and Silicon Valley Bank with a fixed 7.55% rate maturing January 1, 2017, and regulatory developments affecting partners. The FDA requested that patients no longer be dosed with rHuPH20 in Baxter's HyQvia program pending additional preclinical data, and ViroPharma discontinued a Phase 2 Cinryze study. Baxter has stated it intends to resubmit the HyQvia BLA before the end of 2013.
- 2013-Q2Aug 7, 2013
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2013
Halozyme Therapeutics, Inc. reported a net loss of $22.9 million for the three months ended June 30, 2013, compared with $14.0 million in the prior-year quarter, and a six-month net loss of $42.2 million versus $29.1 million. Total revenues for the quarter were $14.5 million (up from $7.8 million), driven mainly by reimbursements for research and development services and rHuPH20 API supply, particularly for Roche. Product sales, net, rose to $3.1 million from $0.5 million, reflecting Hylenex recombinant sales and first API sales for HyQvia following its European approval in May 2013. Research and development expenses increased to $28.0 million for the quarter, reflecting manufacturing activity to support collaborator launches and higher clinical trial spending on the more physiologic insulin and PEGPH20 programs. As of June 30, 2013, cash, cash equivalents and marketable securities totaled approximately $76.0 million, compared with $99.5 million in cash and cash equivalents at December 31, 2012. Net cash used in operating activities was $21.7 million for the six months. The company stated it believes current cash will fund operations for at least the next twelve months, and it anticipates total net cash burn of approximately $45 to $50 million for 2013. It also disclosed that it does not expect revenues to be sufficient to fund operations until 2014 at the earliest, and that it may need additional financing. Stockholders' equity fell to $11.1 million from $48.9 million, and the accumulated deficit reached $340.8 million. The filing also reports regulatory and pipeline developments. The FDA issued a complete response letter for Baxter's HyQvia BLA in August 2012, and ViroPharma discontinued a Phase 2 Cinryze study with rHuPH20 after antibody findings. Roche received a positive CHMP opinion for subcutaneous Herceptin in June 2013, and a Phase 1b PEGPH20 pancreatic cancer study reported a 42 percent overall response rate, leading to a Phase 2 trial. The company also noted a $4 million payment expected in the third quarter of 2013 upon Baxter's first commercial sale of HyQvia.
- 2013-Q1May 8, 2013
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2013
Halozyme Therapeutics, Inc. reported a net loss of $19.3 million for the three months ended March 31, 2013, compared with $15.1 million in the same period of 2012. Total revenues rose to $11.8 million from $7.4 million, driven by $10.3 million of revenues under collaborative agreements and $1.5 million of product sales of Hylenex recombinant. Research and development expenses increased to $22.0 million from $15.9 million, primarily due to higher manufacturing activities to support potential collaborator launches and higher clinical trial activity in the more physiologic insulin and PEGPH20 programs. At March 31, 2013, the company had cash, cash equivalents and marketable securities of approximately $87.4 million, down from $99.5 million in cash and cash equivalents at December 31, 2012. Net cash used in operating activities was $10.8 million for the quarter. Management stated its current cash is sufficient to fund operations for at least the next twelve months, anticipates total net cash burn of approximately $45 to $50 million for 2013, and does not expect revenues to be sufficient to fund operations until 2014 at the earliest. The company also carries a $30 million secured term loan from Oxford Finance LLC and Silicon Valley Bank, fully drawn in December 2012. The filing notes the FDA's complete response letter for Baxter's HyQ BLA, which requested additional preclinical data on non-neutralizing antibodies against rHuPH20. Management stated it does not believe the issues will significantly affect its proprietary and other collaboration candidates, though it acknowledged the concerns could be raised by regulators in the future. Accumulated deficit reached $317.9 million as of March 31, 2013.
- 2012-Q3Nov 8, 2012
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2012
Halozyme Therapeutics, Inc. reported a net loss of $20.0 million, or $(0.18) per share, for the three months ended September 30, 2012, compared with net income of $5.2 million, or $0.05 per share, in the prior-year quarter. For the nine months ended September 30, 2012, the net loss was $49.1 million, or $(0.44) per share, versus a net loss of $1.4 million, or $(0.01) per share, a year earlier. Total revenues for the nine months were $20.5 million, down from $53.7 million, mainly because the prior-year period included the recognition of deferred revenue tied to the termination of the Hylenex Collaboration with Baxter and one-time upfront payments from the ViroPharma and Intrexon collaborations. Research and development expenses rose to $51.5 million for the nine months, and SG&A rose to $17.8 million, reflecting manufacturing activities supporting collaborator product launches and expansion of the commercial department ahead of the December 2011 reintroduction of Hylenex recombinant. The balance sheet strengthened over the period. Cash and cash equivalents were $87.6 million at September 30, 2012, up from $52.8 million at December 31, 2011, after net proceeds of $81.5 million from a February 2012 public offering of 7.82 million shares at $10.61 per share. The company stated that its current cash will be sufficient to fund operations for at least the next twelve months, and it anticipates total net cash burn of approximately $60 to $65 million for 2012. It does not expect revenues to be sufficient to fund operations until 2014 at the earliest, and it may need additional financing. Accumulated deficit reached $294.2 million. The filing also highlights regulatory developments affecting the Baxter HyQ program. On August 1, 2012, the FDA's CBER issued a complete response letter for Baxter's HyQ BLA, citing non-neutralizing antibodies against rHuPH20, and requested that patients no longer be dosed with rHuPH20 in the HyQ program. ViroPharma's Cinryze combination studies were placed on temporary clinical hold and later allowed to resume on September 21, 2012, after FDA guidance. The company stated that FDA confirmed no action was needed against Hylenex recombinant. Management expects the HyQ delays to extend regulatory timelines for the affected programs.
- 2012-Q2Aug 9, 2012
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2012
Halozyme Therapeutics, Inc. reported a net loss of $14.0 million, or $(0.13) per share, for the three months ended June 30, 2012, compared with net income of $3.1 million, or $0.03 per share, in the year-earlier quarter. For the six months ended June 30, 2012, the net loss was $29.1 million, or $(0.27) per share, versus $6.5 million, or $(0.06) per share, a year earlier. The company attributed the swing primarily to the absence of $18.0 million in one-time upfront payments from the ViroPharma and Intrexon partnerships, which were recognized in the prior-year period, together with higher operating expenses. Total revenues for the six months were $15.2 million, of which $14.5 million was collaborative agreement revenue, while research and development expense rose to $32.0 million and selling, general and administrative expense rose to $12.2 million, reflecting the reintroduction of Hylenex recombinant in December 2011. The balance sheet strengthened over the period. Cash and cash equivalents were $102.0 million at June 30, 2012, up from $52.8 million at December 31, 2011, after an February 2012 public offering of 7.82 million shares at $10.61 per share that generated approximately $81.5 million in net proceeds. Management believes current cash will fund operations for at least the next twelve months and anticipates total net cash burn of approximately $55 to $60 million for 2012. Net cash used in operating activities was $33.1 million for the six months. The filing also discloses a significant regulatory development. On August 1, 2012, the FDA's CBER issued a complete response letter for Baxter's HyQ biologic license application, requesting additional preclinical data on non-neutralizing antibodies against rHuPH20. CBER has asked that patients no longer be dosed with rHuPH20 in the Baxter and ViroPharma programs, and a temporary clinical hold was placed on the Cinryze and rHuPH20 studies. Management states that CDER has confirmed no action is needed for Hylenex recombinant, and that it does not believe the issues will affect its proprietary product candidates, though it acknowledges there is no assurance these concerns will not be raised by regulators in the future.
- 2012-Q1May 7, 2012
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2012
Halozyme Therapeutics, Inc. reported a net loss of $15.1 million, or $0.14 per share, for the three months ended March 31, 2012, compared to a net loss of $9.6 million, or $0.10 per share, for the same period in 2011. Total revenues were $7.4 million, down slightly from $7.5 million a year earlier, and consisted mainly of revenues under collaborative agreements of $7.3 million. Product sales of Hylenex recombinant were $187,000, following the product's reintroduction to the market in December 2011. Operating expenses rose to $22.6 million from $17.2 million, driven by higher research and development expense of $15.9 million and selling, general and administrative expense of $6.6 million. The company's cash and cash equivalents rose to $116.6 million at March 31, 2012, from $52.8 million at December 31, 2011, primarily due to net proceeds of $81.5 million from a February 2012 public offering of 7,820,000 shares at $10.61 per share. Management believes current cash will fund operations for at least the next twelve months and projects total net cash burn of approximately $55.0 to $60.0 million for 2012. The company stated that its revenues will not be sufficient to fund operations for several years and that it may need to raise additional capital. The filing highlights progress across the pipeline, including Phase 2 Analog-PH20 insulin results, an ongoing Phase 1 trial of PEGPH20 in solid tumors, and a Phase 1/2 trial of HTI-501 in cellulite. It also notes that the FDA requested additional data on Baxter's HyQ BLA in April 2012, which the companies expect will delay the regulatory timeline. The accumulated deficit reached $260.1 million as of March 31, 2012.
- 2011-Q3Nov 8, 2011
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2011
Halozyme Therapeutics, Inc. reported net income of $5,165,193 ($0.05 per basic and diluted share) for the three months ended September 30, 2011, compared with a net loss of $12,409,576 in the prior-year quarter. Total revenues for the quarter were $22,942,428, up from $3,396,507, driven mainly by revenues under collaborative agreements of $21,785,525. The quarter's results were boosted by the recognition of $17.9 million in deferred revenue tied to the termination of the Hylenex Partnership with Baxter, plus a $3.0 million milestone payment from ViroPharma. For the nine months, the company posted a net loss of $1,354,237 (-$0.01 per share), a substantial improvement from a $36,347,976 loss a year earlier, reflecting $18.0 million in upfront license fees from the ViroPharma and Intrexon partnerships and $11.0 million in milestone payments. Operating expenses rose, with research and development expenses of $42,647,265 for the nine months (up from $35,840,475) and selling, general and administrative expenses of $12,237,152. Management attributed the R&D increase mainly to clinical trial activity supporting the ultrafast insulin and PEGPH20 programs. Management expects R&D costs to increase slightly and SG&A to rise as the company plans to reintroduce Hylenex recombinant by the end of 2011. Cash and cash equivalents were $66,329,358 at September 30, 2011, down from $83,255,848 at December 31, 2010, and net cash used in operating activities was $20,796,584 for the nine months. Management stated that current cash is sufficient to fund operations for at least the next twelve months and projected 2011 net cash burn of approximately $30.0 to $35.0 million. The balance sheet shows total stockholders' equity of $27,055,163, deferred revenue of $36,667,445 (non-current), and an accumulated deficit of $226,606,032. The company disclosed that it does not expect revenues to fund operations for several years, and that it may need to raise additional capital through equity, debt, or collaborations, which could dilute existing stockholders.
- 2011-Q2Aug 5, 2011
Halozyme Therapeutics Quarterly Report for Q2 Ended Jun 30, 2011
Halozyme Therapeutics, Inc. reported a net income of $3.1 million, or $0.03 per diluted share, for the three months ended June 30, 2011, compared with a net loss of $12.2 million, or $0.13 per share, in the prior-year quarter. For the six months ended June 30, 2011, the net loss narrowed to $6.5 million, or $0.06 per share, from $23.9 million, or $0.26 per share. The improvement was driven mainly by $18.0 million in upfront license fees from the ViroPharma and Intrexon partnerships, both recognized in the second quarter, and $8.0 million in milestone payments from Roche and Baxter in the six-month period. Total revenues for the quarter were $23.2 million, versus $3.2 million a year earlier. The balance sheet shows cash and cash equivalents of $79.1 million at June 30, 2011, and the company stated it believes that amount is sufficient to fund operations for at least the next twelve months. Management anticipates total net cash burn of approximately $30.0 to $35.0 million for 2011. Operating cash outflow narrowed to $7.4 million for the six months, from $26.4 million a year earlier. Deferred revenue totaled $57.6 million, and the company has an accumulated deficit of approximately $231.8 million. The filing also highlights the termination of the HYLENEX partnership with Baxter, after which Halozyme expects to recognize approximately $7.6 million and $9.3 million of deferred revenue in the third quarter of 2011. The FDA has approved the reintroduction of HYLENEX, which the company expects by the end of 2011. Ongoing development focuses on the ultrafast insulin program and PEGPH20, and research and development expenses were $29.1 million for the six months, up from $23.4 million.
- 2011-Q1May 6, 2011
Halozyme Therapeutics Quarterly Report for Q1 Ended Mar 31, 2011
Halozyme Therapeutics, Inc. reported a net loss of $9.6 million, or $0.10 per share, for the three months ended March 31, 2011, compared with a net loss of $11.8 million, or $0.13 per share, a year earlier. Total revenues rose to $7.5 million from $3.4 million, driven mainly by a $5.0 million clinical milestone payment recognized under the Roche Partnership and higher revenues under collaborative agreements of $7.4 million versus $3.0 million. Research and development expenses increased to $13.8 million from $11.5 million, mainly due to a $4.4 million increase in clinical trial activity supporting the ultrafast insulin program, while product sales fell to $165,000 from $398,000 after the HYLENEX Partnership with Baxter was terminated in January 2011. Liquidity is the key investor consideration. Cash and cash equivalents were $73.8 million at March 31, 2011, down from $83.3 million at December 31, 2010, and net cash used in operating activities was $11.1 million for the quarter. The company states that its cash will be sufficient to fund operations for at least the next twelve months and anticipates total net cash burn of $47.0 to $52.0 million for 2011. Management also states that revenues will not be sufficient to fund operations for several years and that it may raise additional capital, and the filing notes a shelf registration allowing up to $39.8 million of securities to be offered. The filing also highlights the HYLENEX recall in May 2010 and the expected reintroduction of the product in the second half of 2011, subject to FDA review and to negotiation of transition agreements with Baxter. The company's lead proprietary programs are the ultrafast insulin program, with Phase 2 studies expected to report by June 2012, and PEGPH20 for solid tumors. Stockholders' equity declined to $13.5 million from $20.4 million, and the accumulated deficit reached $234.9 million.
- 2010-Q3Nov 5, 2010
Halozyme Therapeutics Quarterly Report for Q3 Ended Sep 30, 2010
Halozyme Therapeutics, Inc. reported a net loss of $12.4 million, or $0.13 per share, for the three months ended September 30, 2010, compared with a net loss of $13.9 million, or $0.16 per share, in the prior-year quarter. For the nine months, the net loss was $36.3 million, or $0.39 per share, versus $45.7 million, or $0.54 per share, a year earlier. Total revenues for the nine months were $10.1 million, driven by $9.4 million in revenues under collaborative agreements with Baxter and Roche, while product sales were only $695,000 following the May 2010 voluntary recall of HYLENEX. Management expects product sales to remain low until HYLENEX is reintroduced, and the timing of that reintroduction depends on a planned meeting with the FDA. The company ended the quarter with cash and cash equivalents of $89.8 million, up from $67.5 million at December 31, 2009, after a September 2010 public offering of 8.3 million shares at $7.25 per share that generated approximately $60.0 million in net proceeds. Management believes current cash is sufficient to fund operations for at least the next twelve months and anticipates total net cash burn of approximately $40.0 to $45.0 million for 2010, excluding the offering proceeds. Stockholders' equity rose to $35.0 million from $6.9 million, and the accumulated deficit stood at $208.4 million. In October 2010 the company completed a reorganization that reduced its workforce by approximately 25 percent, primarily in discovery research and preclinical areas, with a one-time charge expected in the fourth quarter. The company's lead proprietary program is its ultrafast insulin program, and it is also developing PEGPH20 for tumors rich in hyaluronan. Its partnered programs include Enhanze Technology collaborations with Roche and Baxter. The filing also notes a new U.S. patent (No. 7,767,429) covering rHuPH20, with a European counterpart facing an opposition.